Press Release by New Image Group Limited at 9:09 am, 28 May 2010

NZ sleep enhancing milk popular in Taiwan

Taiwanese trials of a New Zealand sleep enhancing milk product proved there was interest. But joint venture partners New Image Group and Somnaceutics have been stunned by the demand for the milk powder-based drink since it launched six weeks ago.

Stephen Lyttelton, chief executive of health and wellness product group New Image (NZX: NEW), says the first shipment of Sleep Time sold out to its 20,000 Taiwanese distributors within half an hour of the product's launch.

He says the demand confirms clinical trials in Taiwan that saw 88% of users report significant sleep improvement. People in the trials kept sleep diaries and gauged the product's effectiveness.

Production in New Zealand is now being ramped up and Somnaceutics is adding more cows to the special dairy herds that produce milk containing a high level of sleep enhancing peptides.

The Auckland-based bio-technology company was established in 2007 to commercialise the discovery that certain cows carried peptides believed responsible for the sleep-enhancing effect of their milk.  The peptides were discovered by Somnaceutics' founding scientist and director Professor Bob Elliott. Prof Elliott, who is also the founding scientist of Living Cell Technologies (ASX: LCT and OTCQX: LVCLY), also developed the proprietary manufacturing process to stabilize the milk, extending the life of certain milk fractions in the body's circulation.

Another Somnaceutics shareholder is its board chairman Gary Pace, a former Fullbright Fellow at the Massachusetts Institute of Technology. Dr Pace is also a director of ResMed (NYSE:RMD and ASX:RMD.AX) which develops, manufacturers and markets products for the screening, treatment and management of sleep and respiratory disorders.

The joint venture in Taiwan came about after New Image's research among its more than 5000 direct selling distributors in Taiwan had shown it that sleep deprivation is a real concern to Taiwanese living a high-pressure lifestyle. A study by the Taiwan Society of Sleep Medicine also showed that the number of Taiwanese suffering from lack of sleep has doubled in three years to 22% of the country's population of 23 million now having chronic insomnia and up to 60% suffering some form of sleep deprivation.

New Image sought the exclusive right to distribute the Somnaceutics milk powder through its direct selling channels in Taiwan and the joint venture partnership was established late last year.

Guy Wills, Somnaceutics' chief executive, says the flavoured milk powder, which is mixed with a small amount of water, has a natural soporific effect and has been shown in clinical trials to provide a statistically significant improvement in quality of sleep and most notably on increasing time spent in the important rapid eye movement (REM) sleep phase.

"Taiwanese like the fact that it is a natural product that has been scientifically developed and is clinically proven," Mr Wills says. "The product was pretested with Taiwanese consumers and this helped fine tune elements such as flavour, formulation and packaging. The Taiwanese also like that it not only helps with sleeping, but also has strong nutritional benefits. It has less than 1% fat and is lactose free. Magnesium has been added to help muscles relax and for utilisation of calcium."

Somnaceutics won the Cawthron Institute award for Innovation in Science and Technology for Sleep Time in the Natural Products New Zealand Industry Awards last month.

Somnaceutics, co-founded by Pacific Channel, won the Science Innovation Award at the NZ Natural Products Industry Summit for its natural sleep enhancing milk product. Somnaceutics’ marketing partner, New Image Group Limited (NZX:NEW) won the Export Award. Both awards were announced at the Summit held on 22nd April 2010.
 

See www.naturalproductsnz.org

23 December 2009 - Somnaceutics and NZX listed New Image Group Limited agree to trial sales of Somnaceutics sleep enhancing beverage in Taiwan.

New Image Group is a large seller of branded New Zealand colostrum in Taiwan. The market trial is intended to demonstrate consumer uptake through sales and to obtain consumer feedback.

Press release...

5 August 2009 – Pacific Channel Ltd has supported Living Cell Technologies, a New Zealand global leader in cell therapy, in raising A$4.2 million through the issue of new shares.

Pacific Channel managed the New Zealand side of the trans-Tasman capital raising for LCT which is listed on the Australian Stock Exchange (ASX).

The successful capital raising involved the placement of 5.5 million ordinary LCT shares at 16.5 Australian cents per share with two options attached to every five shares.

Pacific Channel Director, Brent Ogilvie, said “it is pleasing that New Zealand investors supported LCT which will use the A$4.2 million to conduct clinical trials of a new treatment for Type 1 diabetes, DIABECELL®, in both New Zealand and Russia.”

The most recent patient taking part in trials, who had Type 1 diabetes for 15 years, became the second person to no longer require insulin injections after treatment.

Mr Ogilvie said “this is the third capital raising in 2009 in which Pacific Channel has worked with Professor Bob Elliott, the prominent New Zealander who co-founded LCT in 1987.

“In May, Pacific Channel raised a second round of capital for Sleep Limited, now Somnaceutics Limited, and in July raised first round capital for Breathe Easy Limited, a company developing a treatment for cystic fibrosis. Somnaceutics is commercialising a milk product to help people sleep,” he said.

LCT’s DIABECELL® treatment for diabetes involves implanting insulin-producing cells into patients to regulate glucose levels.  The cells, taken from healthy Auckland Island pigs, are encapsulated with alginate to ensure acceptance by the body’s immune system.